Cargando…

Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms

BACKGROUND: Novel methods are necessary to reduce morbidity and mortality of patients suffering from infections with Pseudomonas aeruginosa. Being the most common infectious species of the Pseudomonas genus, P. aeruginosa is the primary Gram-negative etiology responsible for nosocomial infections. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Armijo, Leisha M., Wawrzyniec, Stephen J., Kopciuch, Michael, Brandt, Yekaterina I., Rivera, Antonio C., Withers, Nathan J., Cook, Nathaniel C., Huber, Dale L., Monson, Todd C., Smyth, Hugh D. C., Osiński, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029462/
https://www.ncbi.nlm.nih.gov/pubmed/32070354
http://dx.doi.org/10.1186/s12951-020-0588-6
_version_ 1783499172648845312
author Armijo, Leisha M.
Wawrzyniec, Stephen J.
Kopciuch, Michael
Brandt, Yekaterina I.
Rivera, Antonio C.
Withers, Nathan J.
Cook, Nathaniel C.
Huber, Dale L.
Monson, Todd C.
Smyth, Hugh D. C.
Osiński, Marek
author_facet Armijo, Leisha M.
Wawrzyniec, Stephen J.
Kopciuch, Michael
Brandt, Yekaterina I.
Rivera, Antonio C.
Withers, Nathan J.
Cook, Nathaniel C.
Huber, Dale L.
Monson, Todd C.
Smyth, Hugh D. C.
Osiński, Marek
author_sort Armijo, Leisha M.
collection PubMed
description BACKGROUND: Novel methods are necessary to reduce morbidity and mortality of patients suffering from infections with Pseudomonas aeruginosa. Being the most common infectious species of the Pseudomonas genus, P. aeruginosa is the primary Gram-negative etiology responsible for nosocomial infections. Due to the ubiquity and high adaptability of this species, an effective universal treatment method for P. aeruginosa infection still eludes investigators, despite the extensive research in this area. RESULTS: We report bacterial inhibition by iron-oxide (nominally magnetite) nanoparticles (NPs) alone, having a mean hydrodynamic diameter of ~ 16 nm, as well as alginate-capped iron-oxide NPs. Alginate capping increased the average hydrodynamic diameter to ~ 230 nm. We also investigated alginate-capped iron-oxide NP-drug conjugates, with a practically unchanged hydrodynamic diameter of ~ 232 nm. Susceptibility and minimum inhibitory concentration (MIC) of the NPs, NP-tobramycin conjugates, and tobramycin alone were determined in the PAO1 bacterial colonies. Investigations into susceptibility using the disk diffusion method were done after 3 days of biofilm growth and after 60 days of growth. MIC of all compounds of interest was determined after 60-days of growth, to ensure thorough establishment of biofilm colonies. CONCLUSIONS: Positive inhibition is reported for uncapped and alginate-capped iron-oxide NPs, and the corresponding MICs are presented. We report zero susceptibility to iron-oxide NPs capped with polyethylene glycol, suggesting that the capping agent plays a major role in enabling bactericidal ability in of the nanocomposite. Our findings suggest that the alginate-coated nanocomposites investigated in this study have the potential to overcome the bacterial biofilm barrier. Magnetic field application increases the action, likely via enhanced diffusion of the iron-oxide NPs and NP-drug conjugates through mucin and alginate barriers, which are characteristic of cystic-fibrosis respiratory infections. We demonstrate that iron-oxide NPs coated with alginate, as well as alginate-coated magnetite–tobramycin conjugates inhibit P. aeruginosa growth and biofilm formation in established colonies. We have also determined that susceptibility to tobramycin decreases for longer culture times. However, susceptibility to the iron-oxide NP compounds did not demonstrate any comparable decrease with increasing culture time. These findings imply that iron-oxide NPs are promising lower-cost alternatives to silver NPs in antibacterial coatings, solutions, and drugs, as well as other applications in which microbial abolition or infestation prevention is sought.
format Online
Article
Text
id pubmed-7029462
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70294622020-02-25 Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms Armijo, Leisha M. Wawrzyniec, Stephen J. Kopciuch, Michael Brandt, Yekaterina I. Rivera, Antonio C. Withers, Nathan J. Cook, Nathaniel C. Huber, Dale L. Monson, Todd C. Smyth, Hugh D. C. Osiński, Marek J Nanobiotechnology Research BACKGROUND: Novel methods are necessary to reduce morbidity and mortality of patients suffering from infections with Pseudomonas aeruginosa. Being the most common infectious species of the Pseudomonas genus, P. aeruginosa is the primary Gram-negative etiology responsible for nosocomial infections. Due to the ubiquity and high adaptability of this species, an effective universal treatment method for P. aeruginosa infection still eludes investigators, despite the extensive research in this area. RESULTS: We report bacterial inhibition by iron-oxide (nominally magnetite) nanoparticles (NPs) alone, having a mean hydrodynamic diameter of ~ 16 nm, as well as alginate-capped iron-oxide NPs. Alginate capping increased the average hydrodynamic diameter to ~ 230 nm. We also investigated alginate-capped iron-oxide NP-drug conjugates, with a practically unchanged hydrodynamic diameter of ~ 232 nm. Susceptibility and minimum inhibitory concentration (MIC) of the NPs, NP-tobramycin conjugates, and tobramycin alone were determined in the PAO1 bacterial colonies. Investigations into susceptibility using the disk diffusion method were done after 3 days of biofilm growth and after 60 days of growth. MIC of all compounds of interest was determined after 60-days of growth, to ensure thorough establishment of biofilm colonies. CONCLUSIONS: Positive inhibition is reported for uncapped and alginate-capped iron-oxide NPs, and the corresponding MICs are presented. We report zero susceptibility to iron-oxide NPs capped with polyethylene glycol, suggesting that the capping agent plays a major role in enabling bactericidal ability in of the nanocomposite. Our findings suggest that the alginate-coated nanocomposites investigated in this study have the potential to overcome the bacterial biofilm barrier. Magnetic field application increases the action, likely via enhanced diffusion of the iron-oxide NPs and NP-drug conjugates through mucin and alginate barriers, which are characteristic of cystic-fibrosis respiratory infections. We demonstrate that iron-oxide NPs coated with alginate, as well as alginate-coated magnetite–tobramycin conjugates inhibit P. aeruginosa growth and biofilm formation in established colonies. We have also determined that susceptibility to tobramycin decreases for longer culture times. However, susceptibility to the iron-oxide NP compounds did not demonstrate any comparable decrease with increasing culture time. These findings imply that iron-oxide NPs are promising lower-cost alternatives to silver NPs in antibacterial coatings, solutions, and drugs, as well as other applications in which microbial abolition or infestation prevention is sought. BioMed Central 2020-02-18 /pmc/articles/PMC7029462/ /pubmed/32070354 http://dx.doi.org/10.1186/s12951-020-0588-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Armijo, Leisha M.
Wawrzyniec, Stephen J.
Kopciuch, Michael
Brandt, Yekaterina I.
Rivera, Antonio C.
Withers, Nathan J.
Cook, Nathaniel C.
Huber, Dale L.
Monson, Todd C.
Smyth, Hugh D. C.
Osiński, Marek
Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
title Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
title_full Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
title_fullStr Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
title_full_unstemmed Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
title_short Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
title_sort antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against pseudomonas aeruginosa biofilms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029462/
https://www.ncbi.nlm.nih.gov/pubmed/32070354
http://dx.doi.org/10.1186/s12951-020-0588-6
work_keys_str_mv AT armijoleisham antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT wawrzyniecstephenj antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT kopciuchmichael antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT brandtyekaterinai antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT riveraantonioc antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT withersnathanj antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT cooknathanielc antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT huberdalel antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT monsontoddc antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT smythhughdc antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms
AT osinskimarek antibacterialactivityofironoxideironnitrideandtobramycinconjugatednanoparticlesagainstpseudomonasaeruginosabiofilms